Off-Label Drug-Eluting Stent Data Weak; Label Should Be Revised – Panel
This article was originally published in The Gray Sheet
Executive Summary
FDA panel members recommended changes to drug-eluting stent labeling that would more clearly indicate differences between on- and off-label use. However, they found that the data was insufficient to make definitive conclusions about risks for unapproved applications, which account for the majority of stent placements
You may also be interested in...
Dr. Maisel Goes To Washington: CDRH Advisor, Critic Joins Senior Staff
CDRH has hired a longtime FDA advisor and sometimes outspoken agency and industry critic to lead efforts to improve the way new science is incorporated into agency policies
Dr. Maisel Goes To Washington: CDRH Advisor, Critic Joins Senior Staff
CDRH has hired a longtime FDA advisor and sometimes outspoken agency and industry critic to lead efforts to improve the way new science is incorporated into agency policies
Harvard’s Maisel Builds An Institute To Spotlight, Explain Device Risks
Harvard cardiologist William Maisel has been an important moderating voice during some of the device industry's most controversial moments in recent years. Of late, he has become a more vocal critic of industry and CDRH and is now building a non-profit institute to help fill what he sees as substantial gaps in data collection and public communication on device safety issues